Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails Bioengineer.org
Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails bioengineer.org
Background: Endometriosis affects 190 million women worldwide, so there is a need for accessible and more comprehensive knowledge regarding the pharmacotherapeutic options that can be offered to patients. This systematic …
Endometriosis (EMs) is increasingly recognized as a chronic inflammatory disease in which innate immune dysregulation plays an important role. Its immunopathological features include macrophage polarization imbalance, with M1-skewed activation in …
Endometriosis is a chronic, inflammatory condition affecting around 10% of reproductive-age women, characterized by the presence of endometrial-like tissue outside of the uterus. The effects of endometriosis include chronic pelvic …
Endometriosis is a prevalent estrogen-dependent inflammatory disorder that compromises women's quality of life and fertility through chronic pelvic pain, inflammation, and reproductive dysfunction. Current clinical management remains largely palliative, with …
Postoperative recurrence remains a major obstacle to durable remission in patients with solid tumors, even after complete macroscopic resection. Growing evidence suggests that surgery creates a transient yet highly permissive …
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? ESMO Daily Reporter
Endometriosis is a prevalent chronic inflammatory gynecological disorder affecting approximately 10% of reproductive-age women worldwide, characterized by endometrial-like tissue outside the uterine cavity. Ectopic lesion growth tracks closely with immune-inflammatory …
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years MSN